

AMENDMENTS TO THE CLAIMS

This claim listing will replace all prior versions, and listings, of the claims in the application.

1-3. **(Cancelled).**

4. **(Currently amended)** A method of treating or ~~preventing~~ inhibiting a cancer in a subject in need of said treating or ~~preventing~~ inhibiting comprising the steps of:

(a) administering to the subject a vaccine composition comprising a component that displays the antigenicity of a cancer cell; and

(b) administering to the subject an amount of a purified heat shock protein preparation, wherein the heat shock protein preparation ~~does not~~ comprises purified
i) unbound heat shock protein, or ii) heat shock protein bound to a molecule that does not
display the immunogenicity of the component.

5-8. **(Cancelled).**

9. **(Previously amended)** The method according to claim 4 wherein the heat shock protein preparation comprises a heat shock protein selected from the group consisting of hsp70, hsp90, gp96, calreticulin, and a combination of any two or more thereof.

10-12. **(Cancelled).**

13. **(Currently amended)** The method according to claim 4 wherein the heat shock protein preparation comprises purified ~~heat shock protein-peptide complex or complexes~~ heat shock protein bound to a molecule that does not display the immunogenicity of the component.

14-16. **(Cancelled).**

17. **(Currently amended)** The method according to claim 4 wherein the heat shock protein preparation comprises purified unbound heat shock protein.

18-20. **(Cancelled).**

21. **(Currently amended).** The method according to claim 4 wherein the heat shock protein preparation comprises ~~heat shock protein-peptide complex~~ heat shock protein bound to a molecule that does not display the immunogenicity of the component and purified unbound heat shock protein.

22-24. **(Cancelled).**

25. **(Previously presented)** The method according to claim 4 wherein the subject is human and the heat shock protein preparation comprises mammalian heat shock protein.

26. **(Previously amended)** The method according to claim 4 wherein the heat shock protein preparation is administered before the administration of the vaccine composition.

27. **(Previously presented)** The method according to claim 4 wherein the heat shock protein preparation is administered concurrently with the administration of the vaccine composition.

28. **(Previously presented)** The method according to claim 4 wherein the heat shock protein is preparation administered after the administration of the vaccine composition.

29. **(Previously presented)** The method according to claim 9 wherein the heat shock protein preparation is administered before the administration of the vaccine composition.

30. **(Previously presented)** The method according to claim 9 wherein the heat shock protein preparation is administered concurrently with the administration of the vaccine composition.

31. **(Previously amended)** The method according to claim 9 wherein the heat shock protein preparation is administered after the administration of the vaccine composition.

32. **(Previously amended)** The method according to claim 13 wherein the heat shock protein preparation is administered before the administration of the vaccine composition.

33. **(Previously amended)** The method according to claim 13 wherein the heat shock protein preparation is administered concurrently with the administration of the vaccine composition.

34. **(Previously amended)** The method according to claim 13 wherein the heat shock protein preparation is administered after the administration of the vaccine composition.

35. **(Previously amended)** The method according to claim 17 wherein the heat shock protein preparation is administered before the administration of the vaccine composition.

36. **(Previously amended)** The method according to claim 17 wherein the heat shock protein preparation is administered concurrently with the administration of the vaccine composition.

37. **(Previously amended)** The method according to claim 17 wherein the heat shock protein preparation is administered after the administration of the vaccine composition.

38. **(Previously presented)** The method according to claim 21 wherein the heat shock protein preparation is administered before the administration of the vaccine composition.

39. **(Previously presented)** The method according to claim 21 wherein the heat shock protein preparation is administered concurrently with the administration of the vaccine composition.

40. **(Previously amended)** The method according to claim 21 wherein the heat shock protein preparation is administered after the administration of the vaccine composition.

41. **(Previously presented)** The method according to claim 21 wherein the heat shock protein preparation and the vaccine composition are both administered on the same day.

42. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a live vaccine, an inactivated vaccine, an attenuated vaccine, a subunit vaccine, a DNA vaccine, a RNA vaccine, or a tumor antigen vaccine.

43. **(Cancelled).**

44. **(Previously presented)** The method according to claim 4 wherein the cancer is selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's

tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, acute lymphocytic leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia leukemia, chronic leukemia, chronic myelocytic leukemia, granulocytic leukemia, chronic lymphocytic leukemia, polycythemia vera, lymphoma, Hodgkin's disease lymphoma, non-Hodgkin's disease lymphoma, multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease.

45. **(Cancelled).**

46. **(Currently amended)** The method of claim 4, 9, 13, 17, 21, 25, 26, 27, 28, 42, or 44, wherein the method is for treating a cancer.

47. **(Currently amended)** The method of claim 4, 9, 13, 17, 21, 25, 26, 27, 28, 42, or 44, wherein the method is for ~~preventing~~ inhibiting a cancer.

48-81. **(Cancelled).**

82. **(Previously presented)** The method according to claim 13 wherein the heat shock protein preparation and the vaccine composition are both administered on the same day.

83. **(Previously presented)** The method of claim 17 wherein the heat shock protein preparation and the vaccine composition are both administered on the same day.

84. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a multivalent vaccine.

85. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a univalent vaccine.

86. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a tumor antigen vaccine.

87. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a KS 1/4 pan-carcinoma antigen-based vaccine, an ovarian carcinoma antigen-based vaccine, a prostatic acid phosphate-based vaccine, a prostate specific antigen-based vaccine, a melanoma-associated antigen p97-based vaccine, a melanoma antigen gp75-based vaccine, a high molecular weight melanoma antigen-based vaccine, a MAGE family of antigens-based vaccine, or a prostate specific membrane antigen-based vaccine.

88. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a protein subunit vaccine.

89. **(Currently amended)** The method according to claim ~~[[13]]~~ 4 or 25 wherein the heat shock protein preparation comprises a purified population of ~~heat shock protein-peptide complexes~~ heat shock protein bound to molecules that do not display the immunogenicity of the component.

90. **(Currently amended)** The method according to claim 17 wherein the heat shock protein preparation comprises purified unbound heat shock proteins that are a combination of two or more heat shock proteins.

91. **(Currently amended)** The method according to claim ~~[[21]]~~ 4 or 25 wherein the heat shock protein preparation comprises (a) a population of ~~heat shock protein-peptide complexes~~ heat shock protein bound to molecules that do not display the immunogenicity of the component, and (b) purified unbound heat shock proteins.

92. **(Cancelled).**

93. **(Currently amended)** The method according to any one of claims 4, 9, 13, 17, 21, 25-41, 44, ~~[[46-47,]]~~ 82, or 90, 89, or 92 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

94. **(Previously presented)** The method according to claim 42 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

95. **(Previously amended)** The method according to claim 84 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

96. **(Previously amended)** The method according to claim 85 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

97. **(Previously amended)** The method according to claim 86 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

98. **(Previously amended)** The method according to claim 87 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

99. **(Previously amended)** The method according to claim 88 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

100. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a tumor-associated antigen vaccine.

101. **(Previously presented)** The method of claim 4 or 25 wherein the vaccine composition is a tumor specific antigen vaccine.

102. **(Previously presented)** The method of claim 4 or 25 wherein heat shock protein in the heat shock protein preparation is present in an amount ranging from 0.1 µg to 1000 µg per administration.

103. **(Previously presented)** The method of claim 4 or 25 wherein heat shock protein in the heat shock protein preparation is gp96 or hsp70 and is present in an amount ranging from 10 µg to 600 µg per administration.

104. **(Previously presented)** The method of claim 4 or 25 wherein heat shock protein in the heat shock protein preparation is gp96 or hsp70, said administering is intradermal, and said heat shock protein is present in an amount ranging from 0.1 µg to 10 µg per administration.

105. **(Previously presented)** The method of claim 4 or 25 wherein heat shock protein in the heat shock protein preparation is hsp90 and is present in an amount ranging from 50 µg to 1000 µg per administration.

106. **(Previously presented)** The method of claim 4 or 25 wherein the heat shock protein in the heat shock protein preparation is hsp90, said administering is intradermal, and said heat shock protein is present in an amount ranging from 5 µg to 50 µg per administration.

107. **(New)** The method according to claim 46 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

108. **(New)** The method according to claim 47 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

109. **(New)** The method according to claim 89 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

110. **(New)** The method according to claim 91 wherein the heat shock protein preparation is administered to the subject in an amount effective to induce or increase an immune response in the subject to the component.

111. **(New)** The method of claim 4 or 9 wherein the heat shock protein preparation and the vaccine composition are both administered on the same day.